BTIG Keeps Buy Rating on Humacyte with $7 Price Target, Zimmerman Maintains Strong Buy Consensus

BTIG analyst Ryan Zimmerman maintains a Buy rating on Humacyte with a $7.00 price target. Zimmerman has a success rate of 39.43% and an average return of -2.3%. The analyst consensus on Humacyte is a Strong Buy with an average price target of $7.50. The company reported a quarterly revenue of $517 thousand and a net profit of $39.14 million for the quarter ending March 31.

Title: Humacyte Reports Q2 2025 Financial Results; Analysts Optimistic

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company specializing in developing universally implantable, bioengineered human tissues, has reported its financial results for the second quarter ended June 30, 2025. The company announced a quarterly loss of $37.7 million, or 24 cents per share, which was wider than analysts' expectations [2]. The biotechnology company reported a quarterly revenue of $301,000, which fell short of the $1 million expected by analysts.

Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte, highlighted the company's progress in the U.S. commercial launch. "During our second quarter of 2025, we continued to execute on our U.S. commercial launch and now have 82 civilian hospitals eligible to purchase Symvess," she said [4]. This substantial increase in eligible hospitals is due to a combination of individual hospital and healthcare system Value Analysis Committee (VAC) approvals. Additionally, Humacyte's inclusion on the Electronic Catalog (ECAT) has made Symvess available to approximately 190 Military Treatment Facilities and U.S. Department of Veterans Affairs (VA) hospitals.

The company also reported that its July product sales exceeded the total sales recorded during the first half of the year, indicating a positive trend in sales momentum. Furthermore, Humacyte achieved its first commercial sale to a U.S. military treatment facility in July, with the facility subsequently re-ordering the product [4].

Analysts remain optimistic about Humacyte's prospects. BTIG analyst Ryan Zimmerman maintains a Buy rating on Humacyte with a $7.00 price target, citing the company's innovative technology and strong pipeline of products. The analyst consensus on Humacyte is a Strong Buy with an average price target of $7.50 [3]. Despite the recent financial results, analysts believe that Humacyte's long-term growth potential and recent clinical trial results will drive the stock price higher.

The company's recent achievements, such as the V007 trial data presentation at the Society of Vascular Surgery conference, further underscore its commitment to innovation and improving patient outcomes. The trial data showed that the acellular tissue engineered vessel (ATEV™) had superior functional patency during the first year compared to the autologous fistula control group, particularly in women and men with diabetes and obesity [4].

Overall, Humacyte's Q2 2025 financial results reflect the challenges faced by the company, but its continued progress in commercialization and strong analyst support suggest that the company remains well-positioned for long-term growth.

References:
[1] https://www.cnn.com/markets/stocks/HUMA
[2] https://www.marketwatch.com/story/humacyte-shares-drop-after-wider-than-expected-2q-loss-ad524b1c
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U02KJ:0-humacyte-inc-expected-to-post-a-loss-of-16-cents-a-share-earnings-preview/
[4] https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-second-quarter-2025-financial-results-and